Released Mar 16, 2020, after the close
10-Q filed Mar 16, 2020, 45 days after period end · 0001654954-20-002696
Q1 2020 · 10-Q
Revenue$4.61M$4.61M +1.0% vs Q1 2019−4.4% vs Q4 2019
Net Income$526.90K$526.90K +11.9% vs Q1 2019+10.3% vs Q4 2019
EPS, diluted—
Gross Profit$1,585,892+7.2%
Operating Income$536,759+14.0%
Operating Cash Flow$1,515,019N/M
Free Cash Flowderived$1,503,693N/M
Margins · derived
Gross margin34.4%+2.0 pt vs Q1 2019
Operating margin11.6%+1.3 pt vs Q1 2019
Net margin11.4%+1.1 pt vs Q1 2019
What the release said
The release
Same quarter
| Metric | Q1 2020 | Q1 2019 | Q1 2018 | Q1 2017 |
|---|---|---|---|---|
| Revenue | $4.61M | $4.57M | $3.73M | — |
| Net Income | $526.90K | $471.02K | -$2.66M | -$382.14K |
| EPS Diluted | — | — | -$0.12 | -$0.02 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pharma-Bio Serv, Inc. · CIK 1304161 · Engraved from SEC EDGAR